ARCTURUS THERAPEUTICS HOLDINGS INC. Form 8-K (Feb. 9, 2022)

Summary

Current report on Form 8-K of Arcturus Therapeutics Holdings Inc., date of report February 9, 2022, filed under Item 5.02. It states that effective February 14, 2022 Dr. Steve Hughes will step down as Chief Medical Officer and will continue to support the company and the company's programs for the immediate future as Strategic Clinical Advisor. Dr. Kelly Lindert, the Senior Vice President and Head of Vaccines, will take on the role of Chief Development Officer, Vaccines. The signature block shows /s/ Joseph E. Payne, dated February 11, 2022.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 9, 2022

ARCTURUS THERAPEUTICS HOLDINGS INC.

(Exact name of registrant as specified in its
charter)

Delaware | 001-38942 | 32-0595345
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.)

10628 Science Center Drive , Suite 250

San Diego , California 92121

(Address of principal executive offices)

Registrant’s telephone number, including
area code: (858) 900-2660

(Former name or former address, if changed since
last report)

Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common stock, par value $0.001 per share | ARCT | The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Principal Officers; Election
of Directors; Appointment of Principal Officers.

Effective February 14, 2022, Dr. Steve Hughes will step down
from his position as Chief Medical Officer of Arcturus Therapeutics Holdings Inc. (the “Company”), and will continue to
support the Company and its programs for the immediate future in the role of Strategic Clinical Advisor. Dr. Kelly Lindert, the
Company’s Senior Vice President and Head of Vaccines, will take on the role of Chief Development Officer, Vaccines, for the
Company.

SIGNATURES

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Arcturus Therapeutics Holdings Inc.
Date: February 11, 2022
By: | /s/ Joseph E. Payne
Name: | Joseph E. Payne
Title: | Chief Executive Officer

File and source

File

SEC_ARCT_8-K_filed2022-02-11_0001193805-22-000265.htm

Size

20,534 bytes

SHA-256

3a7007631c897f905b845d9eba71cfa225a0960ca28defeecbd2227ee83412b1

Our copy

SEC_ARCT_8-K_filed2022-02-11_0001193805-22-000265.htm

Original

www.sec.gov